Molecular Partners (MOLN)

• Market cap: $151M
• 1 day: 4.94%
• 5 days: 1.25%
• 1 month: -19.2%
• 3 months: -7.76%
• 6 months: 7.73%
• Year to date: -4.27%
• 1 year: 14.12%
• 5 years: -79.44%
• 10 years: -79.44%
• Sector: Healthcare
• Industry: Biotechnology

About: Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Employees: 134